Maj‐Linda B. Selenica

The paper identifies citrullination of tau as a novel posttranslational modification in Alzheimer's disease and tauopathy models, showing its association with disease progression.

This study identifies GPRC6A as a key regulator of mTORC1 signaling and tau pathology in tauopathies, showing that targeting GPRC6A could reduce tau accumulation and related neurodegeneration.

This study identifies citrullination as a novel irreversible post-translational modification of TDP-43 linked to structural changes, aggregation, and pathology in TDP-43 proteinopathies.

This study quantifies retinal tau isoforms in early and advanced AD and links them to brain pathology and cognitive status.